Lantheus has three shots on goal to challenge Novartis
Two days after tying up with Point the company outlines plans to dominate PSMA-based prostate cancer screening and treatment.
Lantheus gets to the Point in therapeutics
Lantheus goes further into radioligand therapeutics, but the market thinks its latest push shortchanges Point Biopharma.
Big pharma’s key fourth-quarter data
Merck & Co and Novartis are set for important disclosures as Roche battles with Biogen and Eisai in Alzheimer’s.
Spac listings slow as the hunt for deals continues
Spacs still have their supporters, but SEC scrutiny and mixed post-deal performance mean that the story is losing its lustre.
Radiotherapeutics remain in the deal-making frame
A radionuclide deal between Lantheus and Noria mirrors that done by Novartis and Sofie, among others.
Point’s path leads to a Spac
The radiopharmaceutical researcher was negotiating a series B funding round when it got an offer from a Spac that it could not refuse.